Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly…
Browsing: Multiple Myeloma
Earn CME: https://www.naccme.com/program/20-hemcovid-3 In this webcast, Drs. Joseph R. Mikhael and Nina Shah discuss challenges faced by US healthcare practitioners…
Jesus Berdeja, MD of Sarah Cannon Research Institute discusses the BCMA CAR-T therapy JNJ-4528 in pretreated patients with multiple myeloma.…
Jesus Berdeja, MD of Sarah Cannon Research Institute discusses the CAR-T therapy JNJ-4528 in pretreated patients with multiple myeloma. Read…
Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Ajay Chari…
Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’…
Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’…
Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’…
Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’…
Earn CME: https://www.naccme.com/program/19-lm-05 In this webcast from the ‘Multiple Myeloma: Treatment Challenges and Updates’ symposium during the 2019 Lymphoma &…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the alkylating properties in the treatment of relapsed/refractory multple myeloma. ________________ Oncopeptides highlighted…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses the next steps for the ongoing trial once they receive FDA approval and…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides answers where does melphalan flufenamide fit in the mix of RRMM treatment if broad-spectrum…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses results of the HORIZON phase 2 data in RRMM. ________________ Oncopeptides highlighted its…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the combination of the pivotal phase 2 study, HORIZON and phase 3 study,…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the significance of the latest data findings from the O-12-M1 clinical trial recently…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses the 5 clinical trials for the treatment of relapsed/refractory multiple myeloma: O-12-M1, Horizon,…
Peter M. Voorhees, MD @LevineCancer shares the current thinking regarding treatment algorithms in relapsed/refractory multiple myeloma.
Peter M. Voorhees, MD @LevineCancer explains how daratumumab is changing the way multiple myeloma (MM) patients are treated today.
Peter M. Voorhees, MD @LevineCancer summarizes the design and outcomes of the Phase 2 Griffin study in newly diagnosed multiple…
Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, offers opinion on the most promising…
Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, regarding the role of proteasome inhibitors…
Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, explains the role of daratumumab as…
Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer discusses the data investigating iberdomide presented at ASH…
Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer provides opinion on the role of BCMA CAR-T…
Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer considers the Phase 3 ICARIA-MM study investigating isatuximab…
Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer tells us about the design and outcomes of…
Nikhil Munshi, MD, Professor of Medicine, @HarvardHealth @harvardmed @DanaFarber Director of Basic and Correlative Science, discusses if there is an…
Nikhil Munshi, MD, Professor of Medicine, @HarvardHealth @harvardmed @DanaFarber Director of Basic and Correlative Science, tells us about the outcomes…
Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC explains how JNJ-4528 differs from other CAR-T products.
Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC tells us about the outcomes of the CARTITUDE-1 study…
Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC on how CAR-T cell therapy plays a role in…
Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope tells us about the Phase 3 Dreamm-3 study,…
Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope describes the results of the Phase 1 study…
Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope tells us about the outcomes of the CARTITUDE-1…
Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope elaborates on BCMA-directed strategies for multiple myeloma patients.
Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, offers insight of the Phase 3 ICARIA-MM trial investigating…
Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, tells us about the design and outcomes of the…
Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, explains how novel combination treatment options and sequencing strategies…
Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, elaborates on the role of stem cell transplantation in…
James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, offers his insight on the recent data investigating…
James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, discusses the integration of stem cell transplantation into…
Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA differentiates between various anti-CD-38 monoclonal antibodies and…
Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA discusses the promising data on multiple myeloma…
Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA discusses the role of CAR-T cell therapy…
Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA discusses the role of human BCMA CAR-T…
Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive…
Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive…
Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive…
Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive…